Tesofensine: A Triple Monoamine Reuptake Inhibitor for Weight Loss

This content is provided by Superpower Health for educational and informational purposes only. Tesofensine is not FDA-approved for any indication in the United States. It is not available through Superpower or by prescription in the US. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

‍

Every approved anti-obesity drug approved today either mimics gut hormones or suppresses appetite through a single neurochemical pathway. Neither approach fully addresses the brain's reward circuitry around food — the dopaminergic drive that makes highly palatable food hard to resist independent of hunger. Tesofensine targets that circuitry directly, alongside serotonin and norepinephrine, in a mechanism distinct from the GLP-1 class. It is not FDA-approved in the United States.

Here is how tesofensine works, what the landmark Phase II data showed, why a cardiovascular safety signal stalled US development, and how it compares to the current standard of care in obesity pharmacology.

Key Takeaways

• Regulatory Status: Not FDA-approved in the United States. Approved in Mexico as Tesomet (tesofensine plus metoprolol) and Nupenta (tesofensine monotherapy) for obesity management since 2023.
• Research Stage: Phase II RCT data published (Lancet, 2008); Phase III data supported Mexican approval; no ongoing US Phase III program as of April 2026.
• Availability: Not available by US prescription or through Superpower. Not available through US clinical trials as of April 2026. Mexican-approved product (Tesomet/Nupenta) is accessible under Mexican regulatory authority only. Gray-market US sourcing carries significant safety and legal risk.
• Prescribing information: No US FDA-approved label exists. View registered tesofensine trials (ClinicalTrials.gov).
• How it works: Inhibits reuptake of serotonin, norepinephrine, and dopamine simultaneously, suppressing appetite and modestly increasing energy expenditure.
• What trials show: In the landmark Phase II RCT published in The Lancet in 2008, participants receiving tesofensine 0.5 mg achieved approximately 10% placebo-subtracted weight loss over 24 weeks — roughly double the effect of then-approved anti-obesity drugs. The Lancet Editors issued an expression of concern regarding this trial in 2013; that concern has not been resolved.

As of April 2026, tesofensine has no active US FDA approval pathway and is not available by prescription in the United States. The cardiovascular safety signal identified in Phase II — elevations in blood pressure and heart rate — remains the central reason US development has not progressed. The Mexican approval of the combination product Tesomet (tesofensine plus the beta-blocker metoprolol) represents the most clinically advanced regulatory action to date, addressing the cardiovascular signal through co-administration rather than removing it.

What Is Tesofensine?

Tesofensine is a small-molecule triple monoamine reuptake inhibitor. It blocks the reuptake transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT) simultaneously, increasing the availability of all three neurotransmitters in the synaptic cleft. This mechanism is structurally distinct from the GLP-1 receptor agonist class, which acts primarily through gut-derived hormonal signaling. Tesofensine acts centrally, in the brain.

The compound was originally synthesized by NeuroSearch A/S under the development name NS 2330. It entered clinical development for neurological indications: Parkinson's disease and Alzheimer's disease. The weight-loss repositioning followed a pooled analysis of four randomized double-blind multicenter trials in Parkinson's and Alzheimer's patients (n = 740 tesofensine, 228 placebo) published in 2008 in Obesity by Astrup, Meier, Mikkelsen, and Villumsen, which observed dose-dependent weight reductions (-0.5%, -0.9%, -1.8%, -2.8% at 0.125, 0.25, 0.5, and 1.0 mg versus +0.5% placebo at 14 weeks; p = 0.015 for dose effect) — a placebo-subtracted loss of approximately 4% without diet or lifestyle therapy that prompted a dedicated obesity program.

How Tesofensine Works

Serotonin reuptake inhibition

Serotonin signaling in the hypothalamus contributes to satiety and meal termination. By blocking the serotonin transporter (SERT), tesofensine prolongs serotonergic activity in hypothalamic nuclei involved in appetite regulation. This is the same broad pathway exploited by older anti-obesity agents, but in tesofensine it operates in combination with two additional monoamine mechanisms rather than as an isolated target. The serotonin component contributes primarily to satiety enhancement and reduction in caloric intake.

Norepinephrine reuptake inhibition

Norepinephrine reuptake inhibition (NET blockade) activates adrenergic signaling in the brain and periphery. Centrally, norepinephrine promotes satiety signaling through alpha-adrenergic and beta-adrenergic pathways in the hypothalamus. Peripherally, adrenergic activation increases energy expenditure through thermogenic mechanisms. A 2010 randomized, double-blind, placebo-controlled crossover trial in 32 overweight or moderately obese men (tesofensine 2.0 mg daily for 7 days followed by 1.0 mg daily for 7 days), published in the International Journal of Obesity by Sjödin, Gasteyger, Nielsen, and colleagues, found that tesofensine induced higher ratings of satiety and fullness with lower prospective food intake versus placebo, with no significant effect on 24-hour energy expenditure but a 4.6% increase during the night period (p < 0.05) — evidence consistent with the adrenergic component of its mechanism. The same adrenergic activation that supports weight loss also drives the cardiovascular signal discussed below: elevated blood pressure and heart rate.

Dopamine reuptake inhibition and the hypothalamic mechanism

The dopamine transporter (DAT) inhibition component distinguishes tesofensine most clearly from serotonergic or noradrenergic-only approaches. A 2014 PET imaging study in European Neuropsychopharmacology by Appel, Bergström, Buus Lassen, and colleagues demonstrated dose-dependent dopamine transporter occupancy in humans — direct evidence that the DAT inhibition is pharmacologically active at clinical doses. Preclinical work by Axel, Mikkelsen, and Hansen, published in Neuropsychopharmacology in 2010, showed that tesofensine's appetite suppression in diet-induced obese rats is mediated via indirect alpha-1-adrenoceptor and D1 dopamine receptor pathways, not through direct receptor agonism. A related preclinical study by Hansen, Hansen, Tang-Christensen, and colleagues, published in the European Journal of Pharmacology in 2010, demonstrated sustained weight loss and improved glycemic control in diet-induced obese rats in a head-to-head comparison with sibutramine and rimonabant, supporting tesofensine's differentiation from earlier centrally acting obesity drugs. More recent work by Perez, Luis-Islas, Lopez, and colleagues, published in PLOS ONE in 2024, showed that tesofensine silences GABAergic neurons in the lateral hypothalamus — a mechanistic detail that may help explain why appetite suppression does not fully rebound in the way seen with some earlier agents. Chronic dopaminergic effects have also been studied: van de Giessen, de Bruin, la Fleur, and colleagues, in work published in European Neuropsychopharmacology in 2012, found that long-term tesofensine reduced striatal D2/D3 receptor availability in diet-induced obese rats alongside reductions in food intake and body weight, and a 2013 study by Hansen, Jensen, Overgaard, and colleagues in Pharmacology, Biochemistry and Behavior found tesofensine reversed low forebrain dopamine levels associated with diet-induced obesity — a finding relevant to the dopaminergic reward dysfunction hypothesis of obesity.

Appetite attenuation over time

An important nuance in tesofensine's mechanism is that its appetite-suppressing effect appears to attenuate with continued use even as weight loss is maintained. A 2012 multicenter Phase II trial by Gilbert, Gasteyger, Raben, and colleagues, published in Obesity, included a 24-week double-blind placebo-controlled phase (n = 158, randomized to tesofensine 0.25, 0.5, or 1.0 mg or placebo) and a 24-week open-label extension (n = 113). Composite satiety score rose dose-dependently and correlated with weight loss at 24 weeks (r = 0.36, P < 0.0001); in the 1.0 mg group, satiety scores climbed from 52 ± 17 mm at baseline to 64 ± 13 mm at week 12 before falling back to 55 ± 13 mm at week 24, and returned to baseline (50 ± 17 mm) after drug withdrawal despite sustained weight reduction of -7.2 ± 6.7 kg (P < 0.0001); reintroduction at week 60 restored satiety to 56 ± 17 mm. The authors flagged genuine uncertainty about whether the appetite-suppressant effect truly attenuates over time or whether the lower body weight itself pushes satiety scores back toward baseline — a limitation relevant for clinicians projecting long-term durability from short-term data.

What Clinical Trials Have Found

Phase II: the Astrup et al. Lancet trial (2008)

The landmark evidence for tesofensine comes from a Phase II randomized, double-blind, placebo-controlled trial in 203 adults with obesity across five Danish centers, published in 2008 in The Lancet by Astrup, Madsbad, Breum, and colleagues. Participants were randomized to tesofensine 0.25 mg, 0.5 mg, or 1.0 mg daily or placebo for 24 weeks alongside a mildly hypocaloric diet; the primary outcome was body weight change. Mean weight loss was 4.5% on 0.25 mg, 9.2% on 0.5 mg, and 10.6% on 1.0 mg versus 2.0% on placebo — roughly double the placebo-subtracted effect produced by then-approved anti-obesity agents at comparable timepoints (p < 0.0001 for all active doses vs. placebo). The 1.0 mg dose produced greater weight loss but with a higher rate of adverse events. The 0.25 mg dose produced less weight loss with a more favorable tolerability profile.

A critical caveat applies to this citation. The Lancet Editors issued a formal expression of concern regarding the Astrup et al. 2008 trial in 2013, noting unresolved issues with the study. That expression of concern has not been withdrawn as of April 2026. Readers and clinicians interpreting the Phase II efficacy data should be aware that the foundational publication carries this caveat from the journal of record.

Cardiovascular findings from Phase II

The same Phase II program generated the cardiovascular signal that has defined tesofensine's regulatory trajectory. A 2009 Lancet correspondence by Tsai noted that tesofensine 0.5 mg raised systolic and diastolic blood pressure approximately 4 to 6 mm Hg versus lifestyle-matched weight loss controls — an elevation that occurred on top of weight loss that would otherwise be expected to lower blood pressure. A second Lancet correspondence the same year by Sommet, Pathak, and Montastruc added to the efficacy-safety debate, specifically highlighting cardiovascular and psychiatric adverse-event concerns (flagged in the MeSH indexing as class signals for tesofensine). A 2009 evaluation by Doggrell in Expert Opinion on Investigational Drugs — reviewing the Astrup 2008 Lancet trial — summarized the safety picture directly: tesofensine 0.5 mg significantly reduced weight in obese subjects, but may increase blood pressure, heart rate, and the risk of psychiatric adverse events. This profile — meaningful weight loss offset by sympathomimetic cardiovascular effects — is the core tension that has shaped every subsequent regulatory decision about tesofensine.

Phase III and the Mexican approval

Phase III development did not proceed in the United States or the European Union. The cardiovascular signal from Phase II raised a concern that regulators in those jurisdictions were not prepared to accept without a dedicated cardiovascular outcomes trial — a substantial and expensive undertaking. Development shifted to Mexico. Phase III data from the Mexican program supported the 2023 approval of two products by the Mexican regulatory authority COFEPRIS: Tesomet (tesofensine 0.5 mg combined with metoprolol 50 mg, the beta-blocker co-formulation designed to mitigate cardiovascular effects) and Nupenta (tesofensine monotherapy). The mechanistic rationale for the metoprolol combination was supported by preclinical data published by Bentzen, Grunnet, Hyveled-Nielsen, and colleagues in Obesity in 2013, which showed in diet-induced obese rats that co-administration of metoprolol fully prevented the cardiovascular sympathetic effects of tesofensine while leaving its appetite-suppressing and weight-loss efficacy unaffected. In humans, a Phase II randomized, double-blind, placebo-controlled trial of Tesomet (tesofensine 0.5 mg plus metoprolol 50 mg daily) in 21 adults with hypothalamic obesity by Huynh, Klose, Krogsgaard, and colleagues, published in the European Journal of Endocrinology in 2022, reported a mean placebo-subtracted weight reduction of -6.3% (95% CI -11.3 to -1.3; P = 0.017) over 24 weeks, with 8 of 13 Tesomet participants versus 1 of 8 placebo participants achieving ≥5% weight loss (P = 0.046) and a 5.7 cm waist-circumference reduction that approached but did not reach significance (P = 0.054). Critically, no significant differences in heart rate or blood pressure were observed between groups — the strongest human evidence to date for the combination strategy's safety advantage. The small sample (n = 21, 18 completers) and the atypical pathophysiology of hypothalamic obesity limit generalization to common obesity, and sleep disturbance (50% vs. 13%), dry mouth (43% vs. 0%), and headache (36% vs. 0%) were more frequent on Tesomet; one serious adverse event (exacerbated anxiety requiring discontinuation) occurred in the Tesomet arm.

How Tesofensine Compares to GLP-1 Agonists

The GLP-1 receptor agonist class represents the current standard of care in obesity pharmacology. Tesofensine operates through a fundamentally different mechanism: central monoamine reuptake inhibition versus gut-derived hormonal signaling. No head-to-head trials between tesofensine and any GLP-1 agent have been conducted. Cross-trial comparisons are unreliable due to differences in study design, patient populations, and endpoints.

On magnitude of weight loss, the Phase II tesofensine 0.5 mg result (approximately 10% placebo-subtracted weight loss at 24 weeks, subject to the expression of concern noted above) compares unfavorably to the results reported for newer GLP-1 agents in larger, more recent trials. The STEP 1 Phase 3 trial in 1,961 adults with overweight or obesity, published by Wilding, Batterham, Calanna, and colleagues in the New England Journal of Medicine in 2021, found that participants receiving once-weekly semaglutide 2.4 mg achieved mean body weight reduction of -14.9% versus -2.4% with placebo at 68 weeks (p < 0.001). The SURMOUNT-1 Phase 3 trial in 2,539 adults with obesity or overweight plus at least one weight-related complication, published by Jastreboff, Aronne, Ahmad, and colleagues in the New England Journal of Medicine in 2022, reported mean weight loss of -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg versus -3.1% with placebo at 72 weeks (p < 0.001 for all doses vs. placebo). The modern GLP-1 class also carries a favorable cardiovascular signal: the SELECT trial in 17,604 adults with established cardiovascular disease and obesity but without diabetes, published by Lincoff and colleagues in the New England Journal of Medicine in 2023, showed semaglutide 2.4 mg reduced the composite of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke (6.5% vs. 8.0%; hazard ratio 0.80, 95% CI 0.72-0.90; p < 0.001) over a mean 39.8 months of follow-up — a cardiovascular benefit profile that stands in contrast to tesofensine's cardiovascular risk signal. The pipeline beyond approved GLP-1 monotherapy is moving further from central monoamine strategies rather than toward them. A Phase 2 trial of retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, in 338 adults with obesity, published by Jastreboff, Kaplan, Frías, and colleagues in the New England Journal of Medicine in 2023, reported mean body-weight change of -8.7% at 1 mg, -17.1% at 4 mg, -22.8% at 8 mg, and -24.2% at 12 mg versus -2.1% on placebo at 48 weeks — the largest figure yet reported in an obesity pharmacotherapy trial. A Phase 2 dose-finding trial of cagrilintide, a long-acting amylin analog, in 706 adults with overweight or obesity (plus liraglutide and placebo controls), published by Lau, Erichsen, Francisco, and colleagues in The Lancet in 2021, demonstrated dose-dependent weight loss of 6.0% to 10.8% (0.3-4.5 mg) versus 3.0% on placebo and 9.0% on liraglutide 3.0 mg — underscoring that non-GLP-1 peptide mechanisms can produce meaningful weight loss and that the field's center of gravity has shifted toward peptide and receptor-agonist approaches rather than central monoamine reuptake inhibition.

Mechanism differentiation: tesofensine acts centrally on monoamine transporters and may address the dopaminergic reward circuitry around food in ways the GLP-1 class does not. Whether this mechanistic difference produces a clinically meaningful advantage in specific patient populations has not been established in head-to-head trials. A 2018 review in Drugs by Coulter, Rebello, and Greenway placed tesofensine within the history of centrally acting anti-obesity agents, noting its positioning relative to prior CNS-acting drugs that were ultimately withdrawn due to safety concerns. A contemporaneous review by Srivastava and Apovian, published in Current Obesity Reports in 2018, assessed tesofensine's regulatory and development trajectory alongside other emerging obesity pharmacotherapies. For context on the current FDA-approved landscape against which tesofensine is not yet competing, a 2024 JAMA review by Gudzune and Kushner provides a current summary of approved obesity medications and their respective evidence bases.

Side Effects Reported in Trials

The most commonly reported adverse events in tesofensine trials were sympathomimetic and gastrointestinal in nature. The cardiovascular effects (elevated blood pressure and heart rate) were the most consequential from a regulatory perspective.

Cardiovascular:

• Blood pressure elevation: approximately 4 to 6 mm Hg increase at the 0.5 mg dose versus lifestyle-matched controls, as reported by Tsai in the 2009 Lancet correspondence
• Heart rate elevation: documented in Phase II across multiple dose levels; specifically noted in the 2009 Expert Opinion on Investigational Drugs evaluation by Doggrell

Neuropsychiatric:

• Psychiatric adverse events (including mood disturbance and sleep disruption): identified in Phase II and noted in the Doggrell 2009 safety summary as a class concern given the dopaminergic and noradrenergic mechanism
• Dry mouth, nausea, constipation, and insomnia: consistent with the sympathomimetic and monoaminergic pharmacology

Abuse liability: The DAT inhibition component raises a pharmacological question about abuse potential given the structural similarity of dopamine reuptake inhibitors to stimulants. A single-dose, randomized, double-blind, crossover abuse-liability study by Schoedel, Meier, Chakraborty, and colleagues, published in Clinical Pharmacology and Therapeutics in 2010, enrolled 52 recreational stimulant users and compared tesofensine against bupropion, atomoxetine, D-amphetamine 30 mg (positive control), and placebo across subjective and objective measures over 48 hours post-dose. D-amphetamine showed significantly greater effects than placebo on primary and secondary measures, whereas tesofensine's effects were not significantly different from placebo and were comparable to bupropion and atomoxetine — both unscheduled, US-marketed prescription medications. This study is relevant context for abuse-potential discussions but reflects a single-dose design in stimulant-experienced adults and should not be interpreted as establishing equivalence across repeated supratherapeutic dosing or other populations.

The dose-dependency of adverse events was consistent across Phase II: the 1.0 mg dose produced greater weight loss but more adverse events; the 0.25 mg dose was better tolerated but less effective; the 0.5 mg dose represented the developers' view of an acceptable benefit-risk balance, despite the cardiovascular signal. The Mexican Tesomet formulation addresses this signal through co-administration of metoprolol rather than dose reduction.

Who May Not Be Eligible

Trial exclusion criteria and the compound's pharmacological profile define the populations for whom tesofensine carries heightened concern. The following are based on published trial data and the compound's mechanism:

• Uncontrolled or poorly controlled hypertension (adrenergic activation from norepinephrine reuptake inhibition and the documented blood pressure elevation make this population high-risk)
• History of major cardiovascular events, including myocardial infarction, stroke, or arrhythmia (sympathomimetic cardiovascular effects are the central unresolved safety signal)
• Active psychiatric disorder, including major depressive disorder, bipolar disorder, or psychosis (dopaminergic and noradrenergic activation carries neuropsychiatric risk)
• History of substance use disorder (the DAT inhibition component raises pharmacological concerns in this population, even though abuse-liability studies in stimulant-experienced users showed results comparable to bupropion)
• Concurrent use of monoamine oxidase inhibitors (MAOIs) or other serotonergic agents (risk of serotonin syndrome with triple reuptake inhibition)
• Pregnancy and breastfeeding (no safety data)

These criteria reflect clinical trial design and pharmacological reasoning, not an FDA-approved prescribing label, which does not exist for the US market. Any clinical evaluation of tesofensine in the US occurs outside a regulatory framework of approved prescribing guidance.

Regulatory Status and What Comes Next

As of April 2026, tesofensine is not FDA-approved for any indication in the United States and has no active US regulatory submission. The compound does not appear on the FDA's pipeline of pending new drug applications. The trajectory differs from investigational compounds currently in Phase 3 trials with a projected US NDA: there is no equivalent tesofensine program underway in the US or EU.

The 2023 Mexican approvals (Tesomet and Nupenta by COFEPRIS) represent the highest-level regulatory action to date. Mexican approval does not confer any regulatory status in the US; importing Tesomet or Nupenta into the United States would be subject to FDA import rules and would not constitute access to an approved US medication. Sourcing tesofensine through gray-market channels in the US — including compounding pharmacies operating outside standard regulatory frameworks, offshore suppliers, or research chemical vendors — carries significant and unquantifiable risk: no US regulatory oversight, no manufacturing quality assurance, no pharmacovigilance, and potential legal liability.

A review of new and emerging anti-obesity drug molecules by George, Rajaram, and Shanmugam, published in the Journal of Cardiovascular Pharmacology and Therapeutics in 2014, discussed the cardiovascular risk considerations that have governed regulatory decisions about CNS-acting anti-obesity drugs — context relevant to understanding why a drug with tesofensine's signal profile faces a substantially higher regulatory bar in the US than in markets with different risk-tolerance frameworks. A 2018 review by Srivastava and Apovian in Current Obesity Reports similarly assessed tesofensine's development status as stalled without a clear US pathway forward. Whether a future sponsor pursues a US NDA — potentially with a combination product strategy similar to Tesomet, requiring a cardiovascular outcomes trial as a regulatory condition — is unknown as of this writing.

Understanding Your Metabolic Baseline

Whether or not tesofensine enters the US regulatory pathway, the biomarkers relevant to obesity pharmacotherapy are already measurable. Understanding your metabolic baseline is independently valuable, regardless of which compounds eventually become available or whether you are a candidate for any of them. The markers most directly relevant to the conditions tesofensine targets include: HbA1c, which reflects 90-day average glucose exposure and indicates glycemic status; fasting insulin, which reflects insulin secretion relative to glucose and is a sensitive early indicator of insulin resistance; triglycerides, which are often elevated in metabolic syndrome and track closely with dietary carbohydrate and visceral adiposity; fasting glucose, the direct measure of circulating blood sugar; HDL cholesterol, which trends inversely with metabolic health and visceral fat; and a complete lipid panel including LDL cholesterol. These markers provide a coherent picture of metabolic risk — the territory that obesity pharmacotherapy addresses — independent of which drug is under discussion.

That principle, understanding your biology first and then making decisions with a provider based on what the data shows, is central to Superpower's approach to preventive health. For anyone interested in the weight-loss pharmacology landscape, the biomarkers relevant to metabolic health and weight loss are a concrete place to start. The compounds under investigation will evolve. The value of understanding where your metabolic markers stand will not.

IMPORTANT SAFETY INFORMATION

Tesofensine is NOT FDA-approved for any indication in the United States. No US NDA exists and no active US Phase III program is ongoing as of April 2026. Tesofensine is available in Mexico as Tesomet (tesofensine plus metoprolol) and Nupenta (tesofensine monotherapy) under COFEPRIS approval; these products are not available in the United States through any approved US medical channel. Superpower Health does not prescribe, sell, compound, or facilitate access to tesofensine. This article is provided for educational and informational purposes only.

The landmark Phase II efficacy trial (Astrup et al., Lancet 2008) is the subject of a formal expression of concern issued by the Lancet Editors in 2013 that has not been resolved. Readers and clinicians should interpret Phase II efficacy data with this caveat in mind.

Do not use tesofensine if you have: uncontrolled hypertension; a history of major cardiovascular events (myocardial infarction, stroke, arrhythmia); active or unstable psychiatric disorder; a history of substance use disorder; are pregnant or breastfeeding; or are taking MAOIs or other serotonergic medications. These reflect pharmacological concerns and trial exclusion criteria, not an FDA-approved label.

Warnings: blood pressure elevation (approximately 4–6 mm Hg above weight-loss-expected reduction at 0.5 mg); heart rate elevation (sympathomimetic, dose-dependent); psychiatric adverse events including mood disturbance and insomnia; serotonin syndrome risk with concomitant serotonergic agents; dopaminergic activation with potential neuropsychiatric effects. Long-term safety data are limited; no US regulatory pharmacovigilance program exists.

Common side effects reported in trials: dry mouth; nausea; constipation; insomnia; elevated blood pressure; elevated heart rate; mood changes.

Gray-market sourcing of tesofensine in the United States (through unregulated compounders, offshore suppliers, or research chemical vendors) carries significant and unquantifiable risk: no US manufacturing oversight, no quality assurance, no pharmacovigilance, and potential legal liability. Superpower strongly discourages sourcing tesofensine through any non-approved channel.

No FDA-approved prescribing information exists. For registered clinical trial information, see ClinicalTrials.gov.

Additional Questions

What is Tesomet and how does it differ from tesofensine alone?

Tesomet is a fixed-dose combination product containing tesofensine 0.5 mg plus metoprolol 50 mg, approved in Mexico in 2023. Metoprolol is a selective beta-1 adrenergic blocker that counteracts the heart rate and blood pressure elevation produced by tesofensine's noradrenergic mechanism, without substantially interfering with its appetite-suppressing effects. Preclinical data in diet-induced obese rats, and Phase II human data in hypothalamic obesity, support the combination strategy's ability to preserve efficacy while reducing cardiovascular signal. Tesomet is not available in the United States.

Is tesofensine a peptide?

No. Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide. It is sometimes found in searches for "tesofensine peptide" because it is discussed in the same clinical context as peptide-based weight-loss compounds and GLP-1 agents, but it belongs to the monoamine reuptake inhibitor drug class. Its mechanism is pharmacologically closer to antidepressants (SNRIs, NDRIs) than to the incretin-based peptides.

Does tesofensine have abuse potential?

An abuse-liability study by Schoedel and colleagues published in Clinical Pharmacology and Therapeutics in 2010 found that tesofensine showed no greater abuse potential than bupropion or atomoxetine in recreational stimulant users — both marketed US prescription medications. The dopamine transporter inhibition component raises pharmacological questions given the overlap with stimulant mechanisms, but the clinical data available to date do not support classifying tesofensine as having high abuse potential comparable to amphetamines or cocaine. Long-term real-world abuse-liability data from approved markets are limited given the recency of the Mexican approval.

What is tesofensine's origin?

Tesofensine was originally developed as NS 2330 by NeuroSearch A/S for neurological indications. A randomized Phase II trial in early Parkinson's disease by Hauser, Salin, Juhel, and Konyago in Movement Disorders in 2007 found no significant motor improvement, and the follow-up ADVANS trial in advanced Parkinson's with motor fluctuations by Rascol, Poewe, Lees, and colleagues in Archives of Neurology in 2008 reported only modest benefit alongside higher adverse events at higher doses. Population pharmacokinetic modeling of NS2330 in Alzheimer's disease patients was published by Lehr, Staab, Tillmann, and colleagues in the British Journal of Clinical Pharmacology in 2007, confirming tesofensine's active development for Alzheimer's before obesity repositioning. Additional PK/PD modeling of tesofensine and its active metabolite M1 was reported by Lehr, Staab, Tillmann, and colleagues in the British Journal of Pharmacology in 2008, establishing the half-life and metabolite kinetics that continue to inform dosing in the current obesity program. An incidental observation that patients in these neurological trials lost substantial weight on tesofensine led Astrup and colleagues to conduct the retrospective analysis published in Obesity in 2008, which initiated the obesity development program.